Our Center for Clinical Research
The staff in endoscopy is outstanding on every level.
 
-- Anonymous, Patient Satisfaction Survey, 2011 

GAC Center for Clinical Research Excellence

WE ARE ACTIVELY RECRUITING PATIENTS FOR THE FOLLOWING CLINICAL TRIALS

IRRITABLE BOWEL SYNDROME WITH DIARRHEA - CLICK HERE 

ULCERATIVE PROCTITIS - SIGMOIDITIS - CLICK HERE

 
Our Center for Clinical Research was established in 1993 to assist our physicians in their quest for new treatment options. By applying their clinical experience and knowledge to academic research in digestive disease all of our patients have benefited by new therapies not yet offered to the general public. The center is staffed by experienced certified principal research investigators (physicians) and clinical research coordinators. We have extensive experience in both national and international research trials. Since the inception of the center we have worked with the following sponsors (pharmaceutical companies)/CRO’s (Contract Research Organizations)
 
  • Abbot Immunology
  • Baxter Pharmaceuticals
  • Celltech
  • Centocor
  • Luitpold
  • National Cancer Institute
  • Novartis
  • Pfizer
  • Romark
  • Serono
  • Sucampo
  • TAP Pharmaceuticals
  • ICON
  • Kendle
  • Paragon
  • Ovation
  • Parexel
  • PPD (Pharmaceutical Product Development)
  • PRA
  • Premier
  • Quintiles, Inc.
  • Solvay

What is a Clinical Trial?

Clinical trials are research studies that evaluate the effectiveness of new medications or procedures to improve existing treatment methods and develop new ones. Over the years we have participated in clinical trials for colon cancer prevention, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), constipation, and gastroesophageal reflux disease (GERD) to name a few.

Is a Clinical Trial Right for You?

Participating in a clinical trial is a very significant, personal choice. We provide information on our research studies so that you can stay abreast of the latest research and, if you choose, discuss with your doctor the possibility of participating in a clinical trial.
 

Our Facility

The research facilities were designed to ensure the timely and accurate collection of research data. We have an extensive patient database to mine for future clinical trials. Our facility includes an area to draw blood, locked -20°C freezer, locked refrigerator and separate locked medication area, EKG, IV infusion area with monitored IV pumps, an independent endoscopy suite and dedicated secure phone/fax lines to ensure patient privacy. 
 

Open Clinical Research Trials

We are actively enrolling patients in the following studies.
 

A. Study #: 27018966IBS2001 Irritable Bowel Syndrome with Diarrhea

 
Study Title: A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Dose-ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients with Irritable Bowel Syndrome with Diarrhea.
 
It is planned that 580 to 850 people with Irritable Bowel Syndrome (IBS) -Diarrhea, 18 years of age to 65 years of age will participate in this study. Participation will last about 18 weeks or approximately 4.5 months and will consist of 8 visits.
 
The study drug and all tests and procedures for diarrhea, and visits required by the study, are provided at no cost to the patient. If the patient completes the study, they will be paid a total of $360.00 for their participation.
 
To qualify, the patient will have to meet a list of inclusion and exclusion criteria that will be discussed in detail at their screening visit.

B. Study #” BUCF3002 Ulcerative Proctitis or Proctosigmoiditis

 
Study Title: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2mg/25ml BID for Two Weeks, Followed by 2mg/25ml QD for Four Weeks) Versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis.
 
The sponsor of this study, Salix Pharmaceuticals, is looking at the use of budesonide foam administered rectally, and evaluating the safety and effectiveness of budesonide foam compared to placebo in subjects with ulcerative proctitis or proctosigmoiditis.
 
Participation this study is expected to last about 11 weeks and will involve up to 8 visits. Approximately 430 patients will participate. Patients may receive up to $475.00 for participating and completing the study.
 
To qualify, the patient will have to meet a list of inclusion and exclusion criteria that will be discussed in detail at their screening visit.
 
For more information, please contact our research coordinator by calling 216-593-7461, or sending an email to research@gastro-associates.com.